Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents

Ntanasis-Stathopoulos, Ioannis, Karalis, Vangelis, Gavriatopoulou, Maria, Sklirou, Aimilia D.; Malandrakis, Panagiotis, Migkou, Magdalini, Roussou, Maria, Fotiou, Despina, Alexopoulos, Harry, Eleutherakis-Papaiakovou, Evangelos, Theodorakakou, Foteini, Kastritis, Efstathios, Trougakos, Ioannis P.; Dimopoulos, Meletios A.; Terpos, Evangelos

Ntanasis-Stathopoulos, Ioannis, Karalis, Vangelis, Gavriatopoulou, Maria, Sklirou, Aimilia D.; Malandrakis, Panagiotis, Migkou, Magdalini, Roussou, Maria, Fotiou, Despina, Alexopoulos, Harry, Eleutherakis-Papaiakovou, Evangelos, Theodorakakou, Foteini, Kastritis, Efstathios, Trougakos, Ioannis P.; Dimopoulos, Meletios A.; Terpos, Evangelos.

Clinical lymphoma, myeloma & leukemia ; 22(8):S116-S116, 2022.

Article in English | EuropePMC | ID: covidwho-2012175

Search on Google

XML

Collection: Databases of international organizations Database: EuropePMC Topics: Vaccines Language: English Journal: Clinical lymphoma, myeloma & leukemia Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML